Larson, Rebecca C.
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Article History
Accepted: 23 November 2020
First Online: 22 January 2021
Competing interests
: M.V.M. and R.C.L. have intellectual property on certain chimeric antigen receptor (CAR) T cells and antibodies (not yet licensed). M.V.M. receives consulting income from several industry sponsors that market CAR T cell therapies, serves on several scientific advisory boards and has equity in TCR2 and Century Therapeutics.